Skip to main content
Medical information Clinical review pending

Genetic Testing

OncoPro NCCN Lung Cancer Panel with PD-L1 Test

The OncoPro NCCN Lung Cancer Panel with PD-L1 Test identifies genetic mutations and biomarkers in lung cancer, guiding personalized treatment decisions. This comprehensive test analyzes key genes like EGFR, ALK, and PD-L1.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
20 mL whole blood in 2 Streck tubes; 8 mL whole blood in 1 Lavender Top (EDTA) tube (with preservative from the collection kit).
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for this blood test. Confirm with the laboratory before booking.
Test priceKSh 280,800

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the OncoPro NCCN Lung Cancer Panel with PD-L1 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with diagnosed lung cancer seeking treatment options.
  • ✓Patients with lung cancer whose tumor characteristics are unknown.
  • ✓Individuals with symptoms suggestive of lung cancer (e.g., persistent cough, chest pain, weight loss).
  • ✓Patients considering targeted therapy or immunotherapy for lung cancer.
  • ✓Individuals with a family history of lung cancer.
  • ✓Smokers or former smokers concerned about lung cancer risk.
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations and PD-L1 expression in lung cancer tissue or blood, guiding oncologists in selecting targeted therapies and immunotherapy, potentially improving treatment outcomes and prognosis.
The OncoPro NCCN Lung Cancer Panel with PD-L1 Test is a diagnostic tool used to identify specific genetic mutations and biomarkers associated with lung cancer. This information is vital for oncologists to develop personalized treatment strategies based on the unique molecular characteristics of a patient's tumor. Utilizing advanced next-generation sequencing technology, this test aims to improve treatment outcomes for individuals diagnosed with lung cancer.

This comprehensive panel tests for several key genetic components, including EGFR, ALK, ERBB2, BRAF, MET, RET, ROS1, NTRK1, KRAS, MSI, and PD-L1. Understanding these components helps in determining the biological behavior of the cancer and identifying the most effective treatment options.

Taking this test can help identify specific mutations that inform treatment decisions, potentially providing access to targeted therapies. It offers a deeper understanding of the disease, aiding in better management and care, and may facilitate opportunities for clinical trials.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for this blood test. Confirm with the laboratory before booking.
Sample20 mL whole blood in 2 Streck tubes; 8 mL whole blood in 1 Lavender Top (EDTA) tube (with preservative from the collection kit).
MethodologyNext-Generation Sequencing (NGS) and immunohistochemistry (for PD-L1). Confirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test identifies specific mutations and biomarkers but does not guarantee a specific treatment response. Results should be interpreted in the context of the patient's overall clinical picture. The test may not detect all possible mutations associated with lung cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test analyzes specific genetic mutations and the PD-L1 biomarker in lung cancer cells to help guide treatment decisions.
This test is typically recommended for individuals diagnosed with lung cancer to help determine the best course of treatment.
The test looks for changes in genes like EGFR, ALK, BRAF, KRAS, and others, as well as the level of the PD-L1 protein.
The test requires blood samples collected in specific tubes. Please follow the laboratory's instructions for collection and transport.
Turnaround time varies. Please contact the laboratory for the current estimated timeframe.
Insurance coverage varies. It is best to check with your insurance provider regarding coverage for this specific test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp